|1.||Funahashi, Yasuhiro: 3 articles (08/2014 - 11/2002)|
|2.||Semba, Taro: 3 articles (08/2014 - 11/2002)|
|3.||Wakabayashi, Toshiaki: 3 articles (08/2014 - 11/2002)|
|4.||Asada, Makoto: 2 articles (08/2014 - 02/2004)|
|5.||Keizer, Ron J: 2 articles (06/2011 - 04/2009)|
|6.||Sugi, Naoko Hata: 2 articles (02/2004 - 11/2002)|
|7.||Yoshimatsu, Kentaro: 2 articles (02/2004 - 11/2002)|
|8.||Yamamoto, Yuji: 2 articles (02/2004 - 11/2002)|
|9.||Uenaka, Toshimitsu: 1 article (08/2014)|
|10.||Ito, Ken: 1 article (08/2014)|
06/01/2011 - "Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies."
04/01/2009 - "The aim of this study was to assess the population pharmacokinetics (PopPK) of the novel oral anti-cancer agent E7820. "
02/15/2004 - "Immunohistochemical analyses using anti-CD31 antibody showed that E7820 significantly reduced microvessel density in orthotopically implanted KP-1 tumor. "
02/15/2004 - "Moreover, E7820 significantly inhibited the growth of KP-1 and human colon tumor Colo320DM cells orthotopically implanted in the pancreas and cecum, respectively. "
08/01/2014 - "Immunohistochemical analysis indicated that combined treatment with E7820 and erlotinib significantly decreased microvessel density and increased apoptosis of tumor-associated endothelial cells compared with use of only one of the agents. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|2.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|3.||Biological Markers (Surrogate Marker)
|4.||Messenger RNA (mRNA)
|5.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|7.||erlotinib (CP 358,774)
|1.||Heterologous Transplantation (Xenotransplantation)